IIa类HDAC抑制剂可增强多发性骨髓瘤

ClassIIaHDACinhibitionenhancesERstress-mediatedcelldeathinmultiplemyeloma

Histonedeacetylase(HDAC)inhibitorshavebeenextensivelyinvestigatedastherapeuticagentsincancer.However,thebiologicalroleofclassIIaHDACs(HDAC4,5,7and9)incancercells,includingmultiplemyeloma(MM),remainsunclear.RecentstudiesshowHDAC4interactswithactivatingtranscriptionfactor4(ATF4)andinhibitsactivationofendoplasmicreticulum(ER)stress-associatedproapoptotictranscriptionfactorC/EBPhomologousprotein(CHOP).Inthisstudy,wehypothesizedthatHDAC4knockdownand/orinhibitioncouldenhanceapoptosisinMMcellsunderERstressconditionbyupregulatingATF4,followedbyCHOP.HDAC4knockdownshowedmodestcellgrowthinhibition;however,itmarkedlyenhancedcytotoxicityinducedbyeithertunicamycinorcarfilzomib(CFZ),associatedwithupregulatingATF4andCHOP.ForpharmacologicalinhibitionofHDAC4,weemployedanovelandselectiveclassIIaHDACinhibitorTMP,aloneandin







































北京白癜风专业的医院
北京哪里有治疗白癜风的医院



本文编辑：佚名
转载请注明出地址  http://www.iqoas.com/lcbx/1733.html